methyl (2S,3S)-3-<<(1,1-dimethylethoxy)carbonyl>amino>-2-hydroxy-4-methylpentanoate | 134359-91-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (2S,3S)-3-<<(1,1-dimethylethoxy)carbonyl>amino>-2-hydroxy-4-methylpentanoate
• 英文别名: tert-butyl (1S,2S)-1-(methoxycarbonyl)-1-hydroxy-3-(methylbutan-2-yl)carbamate；methyl (2S,3S)-3-{[(1,1-dimethylethoxy)carbonyl]amino}-2-hydroxy-4-methylpentanoate；methyl (2S,3S)-2-hydroxy-4-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
• CAS: 134359-91-4
• 化学式: C₁₂H₂₃NO₅
• 分子量: 261.318
• InChiKey: CDZJKNXJNNQMDW-IUCAKERBSA-N

物化性质

• 沸点：
  377.8±32.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl (2S,3S)-3-<<(1,1-dimethylethoxy)carbonyl>amino>-2-hydroxy-4-methylpentanoate 在 lithium hydroxide 作用下， 以 乙醇 为溶剂， 生成 (2S,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-methylpentanoic acid
  参考文献：
  名称：

  氟和羟基取代的β-肽的合成及CD光谱

  摘要：

  β -氨基酸1 - 3与在OH和F的取代基α位上已经制备（方案）从天然（小号） - α -氨基酸的丙氨酸，缬氨酸和亮氨酸，以及掺入到β -hexa-和β -heptapeptides 4 - 12。肽合成是根据常规的溶液策略（Boc / Bn保护）与片段偶联进行的。具有（系列a）和不具有（系列b）的新β肽末端保护以HPLC纯形式分离，并通过NMR光谱和MALDI质谱进行表征。CD光谱的化学性质和谱图（图3-5）取决于OH总数，氨基酸残基的组成（OH，F，F 2取代）和构型（l或u）肽链中的F和F取代基，以及所用溶剂（H 2 O，MeOH，CF 3 CH 2 OH，（CF 3）2 CHOH）上。从这些CD光谱不能获得关于结构的可靠线索。只有一个完整的NMR分析就能回答的问题：一）哪些已知的β肽二级结构（图1和2）与OH和F衍生物相容？b）极性和/或氢键主链取代基是否增强了新的二级结构？此外，

  DOI：

  10.1002/hlca.200390150
• 作为产物：
  描述：

  (2RS,3S)-3-amino-2-hydroxy-4-methylpentanoic acid 在 盐酸 、 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 methyl (2S,3S)-3-<<(1,1-dimethylethoxy)carbonyl>amino>-2-hydroxy-4-methylpentanoate
  参考文献：
  名称：

  含有Val-His替代物Val psi [CH（CONH2）NH] His的血管紧张素II类似物的合成和生物学活性。

  摘要：

  将二肽模拟物Val psi [CH（CONH2）NH] His（4）掺入血管紧张素II（AII）类似物中，以提供八肽aralasin衍生物（29）以及四肽类似物19。三个C端四肽（21，25 （和28）也已准备好。测试了所有化合物从兔肾上腺匀浆中置换3H-AII的能力以及在豚鼠回肠上作为AII和AI的拮抗剂的能力。八肽类似物29的活性比亲本肽30低700倍。所有C末端片段19、21、25和28均没有可测量的AII拮抗剂活性。在四个四肽片段中，只有21个显示出任何明显的结合活性。

  DOI：

  10.1021/jm00112a014

文献信息

• Improved Stereoselectivity in Intramolecular S_N2′ Cyclization through Use of Mechanistic Principles
  作者：Ki Park、Woo Seo、Marcus Curtis-Long、Seong Jeong、Tae Jun、Min Yang

  DOI：10.1055/s-2006-958956

  日期：2007.1

  Valine and alanine were converted into the corresponding α-hydroxy-β-amino acids through intramolecular S N 2' cyclization. The novel cyclization protocol relied upon the use of N-benzyl-protected carbamates derived from α-amino acids.

  缬氨酸和丙氨酸通过分子内SN 2' 环化转化为相应的α-羟基-β-氨基酸。新的环化方案依赖于使用衍生自 α-氨基酸的 N-苄基保护的氨基甲酸酯。
• Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use
  申请人：Robinson Clive

  公开号：US20120322722A1

  公开（公告）日：2012-12-20

  The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

  本发明一般涉及治疗化合物领域，更具体地涉及某些丙酮酰胺化合物的公式（X）（为方便起见，以下统称为“PVA化合物”），该化合物在某些情况下抑制尘螨1组蛋白酶过敏原（例如Der p 1、Der f 1、Eur m 1）。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制尘螨1组蛋白酶过敏原，并用于治疗由尘螨1组蛋白酶过敏原介导的疾病和疾病，通过抑制尘螨1组蛋白酶过敏原而得到缓解的疾病和疾病；哮喘；鼻炎；过敏性结膜炎；特应性皮炎；由尘螨引发的过敏症状；由尘螨1组蛋白酶过敏原引发的过敏症状；以及犬类特应性。
• Highly Diastereoselective Epimerization: Stereodivergent Synthesis of α-Hydroxy-β-amino Isopentanoic Acid
  作者：Woo Duck Seo、Marcus J. Curtis-Long、Young Bae Ryu、Jin Hwan Lee、Min Suk Yang、Woo Song Lee、Ki Hun Park

  DOI：10.1021/jo060309m

  日期：2006.6.1

  The high diastereoselectivity of the base-catalyzed epimerization of oxazolidin-2- ones 7 and 8 is shown to depend on the nature of the N-substituent (R group); when R = Bn, the 4,5-trans-product (4S,5R)-9 is formed, whereas when R = H the 4,5-cis-product (4S,5S)-10 is formed, both with > 99:1 dr. The successful hydrolysis of the oxazolidin-2-one group in both cis- and trans-derivatives show this to be a stereodivergent route to enantiopure alpha-hydroxy-beta-amino isopentanoic acids (2R,3S)-1 and (2S,3S)-2.
• The Discovery of Potent, Selective, and Reversible Inhibitors of the House Dust Mite Peptidase Allergen Der p 1: An Innovative Approach to the Treatment of Allergic Asthma
  作者：Gary K. Newton、Trevor R. Perrior、Kerry Jenkins、Meriel R. Major、Rebekah E. Key、Mark R. Stewart、Stuart Firth-Clark、Steven M. Lloyd、Jihui Zhang、Nicola J. Francis-Newton、Jonathan P. Richardson、Jie Chen、Pei Lai、David R. Garrod、Clive Robinson

  DOI：10.1021/jm501102h

  日期：2014.11.26

  Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously. Group 1 allergens of house dust mites (HDM) are meaningful targets in this quest because they are globally prevalent and clinically important triggers of allergic asthma. Group 1 HDM allergens are cysteine peptidases whose proteolytic activity triggers essential steps in the allergy cascade. Using the HDM allergen Der p 1 as an archetype for structure-based drug discovery, we have identified a series of novel, reversible inhibitors. Potency and selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic responses by targeting just a single component, namely, Der p 1. Our findings suggest that these inhibitors may be used as novel therapies for allergic asthma.
• US8541363B2
  申请人：——

  公开号：US8541363B2

  公开（公告）日：2013-09-24